Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial.

Alessandra Dei CasM M MicheliR AldigeriS GardiniF Ferrari-PellegriniM PeriniG MessaM AntoniniV SpigoniG CinquegraniA VazzanaV MorettiP CaffarraR C Bonadonna

Published in: Journal of endocrinological investigation (2024)

NCT03881371, registered on 21 July, 2016.

Keyphrases

cognitive decline
mild cognitive impairment
clinical trial
phase ii
double blind
open label
study protocol
phase iii
randomized controlled trial